Holen Sie sich die Stockscreener-App
45.14
3.44%
-1.61
Handel nachbörslich:
45.14
Schlusskurs vom Vortag:
$46.75
Offen:
$46.4
24-Stunden-Volumen:
388.31K
Relative Volume:
0.75
Marktkapitalisierung:
$1.43B
Einnahmen:
$566.77M
Nettoeinkommen (Verlust:
$48.16M
KGV:
37.93
EPS:
1.19
Netto-Cashflow:
$274.29M
1W Leistung:
-6.31%
1M Leistung:
-0.88%
6M Leistung:
+24.90%
1J Leistung:
+42.94%
1-Tages-Spanne:
$43.99
$46.46
1-Wochen-Bereich:
$43.99
$49.31
52-Wochen-Spanne:
$23.23
$50.79
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Firmenname
Collegium Pharmaceutical Inc
Sektor
Telefon
781-713-3699
Adresse
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
45.14 | 1.48B | 566.77M | 48.16M | 274.29M | 1.19 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-01-10 | Hochstufung | Needham | Hold → Buy |
| 2024-07-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-05-10 | Herabstufung | Needham | Buy → Hold |
| 2024-05-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-08-25 | Bestätigt | Needham | Buy |
| 2023-05-02 | Fortgesetzt | Jefferies | Buy |
| 2022-08-08 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-14 | Eingeleitet | BWS Financial | Sell |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-19 | Fortgesetzt | Jefferies | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2019-04-12 | Fortgesetzt | Janney | Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2018-02-07 | Bestätigt | Needham | Buy |
| 2017-12-05 | Bestätigt | Needham | Buy |
| 2017-09-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-09-13 | Eingeleitet | Gabelli & Co | Buy |
| 2015-06-01 | Eingeleitet | Jefferies | Buy |
| 2015-06-01 | Eingeleitet | Needham | Buy |
| 2015-06-01 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Collegium Pharmaceutical Inc Aktie (COLL) Neueste Nachrichten
Earnings Report: Whats Collegium Pharmaceutical Incs historical returnTake Profit & Reliable Entry Point Trade Alerts - baoquankhu1.vn
The Truth About Collegium Pharmaceutical (COLL): Quiet Stock, Loud Moves – Are You Sleeping On Thi - AD HOC NEWS
Truist Adjusts Price Target on Collegium Pharmaceutical to $58 From $55, Maintains Buy Rating - marketscreener.com
Truist Securities raises Collegium Pharmaceutical stock price target to $58 - Investing.com
Truist Securities raises Collegium Pharmaceutical stock price target to $58 By Investing.com - Investing.com Nigeria
Versor Investments LP Purchases New Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) Presents a Classic Value Case with High Earnings and Low Valuation - Chartmill
What Collegium Pharmaceutical (COLL)'s Revenue Surge and Low Valuation Means For Shareholders - simplywall.st
Ballast Asset Management LP Purchases 27,109 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
(COLL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Collegium Pharmaceutical: Quiet Chart, Loud Questions Around This Specialty Pain Stock - AD HOC NEWS
Market Moves: Is Collegium Pharmaceutical Inc trading at a discount2025 Market Sentiment & Growth Oriented Trade Recommendations - baoquankhu1.vn
Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Strong Revenue Growth and Attractive Valuation with 17.24% Upside Potential - DirectorsTalk Interviews
Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Emerald Mutual Fund Advisers Trust Sells 154,973 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical, Inc. $COLL Shares Sold by Emerald Advisers LLC - MarketBeat
Collegium Pharmaceutical: Buying The Projected Growth For 2026 - Seeking Alpha
(COLL) Risk Channels and Responsive Allocation - Stock Traders Daily
Campbell & CO Investment Adviser LLC Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL - Defense World
SG Americas Securities LLC Raises Position in Collegium Pharmaceutical, Inc. $COLL - Defense World
A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pullback - Sahm
A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Swings - Yahoo Finance
Is It Too Late To Consider Collegium Pharmaceutical (COLL) After A 40% One Year Gain? - simplywall.st
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference - GlobeNewswire
Does Collegium’s 2026 Revenue Guidance After Insider Sales Change The Bull Case For COLL? - simplywall.st
Eastern Bank Buys 45,508 Shares of Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 - AOL.com
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? - Yahoo Finance
Q4 Earnings Estimate for COLL Issued By HC Wainwright - Defense World
Best value stocks to buy for Dec. 18 - MSN
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Needham & Company LLC Forecasts Strong Price Appreciation for Collegium Pharmaceutical (NASDAQ:COLL) Stock - Defense World
Will Authorized Generic Nucynta Launch and New Credit Facility Change Collegium Pharmaceutical's (COLL) Narrative? - Yahoo Finance
(COLL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Can Collegium Pharmaceutical Inc. stock outperform in 2025 bull marketRisk Management & Accurate Trade Setup Notifications - Улправда
Will Collegium Pharmaceutical Inc. stock benefit from commodity pricesMarket Trend Report & AI Powered Buy/Sell Recommendations - ulpravda.ru
Is It Time To Reassess Collegium Pharmaceutical (COLL) After Its Strong Five Year Share Price Run? - Yahoo Finance
How Collegium Pharmaceutical Inc. stock performs in weak economyMarket Trend Review & Free Accurate Trade Setup Notifications - ulpravda.ru
Is Collegium Pharmaceutical Inc. stock positioned for digital transformationMarket Weekly Review & Long Hold Capital Preservation Plans - Улправда
A Look At Collegium Pharmaceutical (COLL) Valuation After 2026 Guidance And Nucynta Authorized Generic Agreements - simplywall.st
Collegium Pharmaceutical (NASDAQ:COLL) Trading Down 6.8% on Analyst Downgrade - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Price Target Cut to $56.00 by Analysts at Barclays - MarketBeat
How Good Is Collegium Pharmaceutical, Inc. (NASDAQ:COLL), When It Comes To ROE? - 富途牛牛
Collegium Pharmaceutical (NASDAQ:COLL) Price Target Raised to $56.00 - MarketBeat
Truist Financial Maintains Collegium Pharmaceutical(COLL.US) With Buy Rating, Maintains Target Price $55 - 富途资讯
COLL FinancialsIncome Statement - Quiver Quantitative
What 6 Analyst Ratings Have To Say About Collegium Pharmaceutical - Benzinga
Collegium Pharmaceutical (NASDAQ:COLL) Cut to “Hold” at Zacks Research - Defense World
Can Collegium Pharmaceutical Inc. stock sustain free cash flow growthJuly 2025 Retail & Daily Growth Stock Tips - Улправда
Finanzdaten der Collegium Pharmaceutical Inc-Aktie (COLL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.21%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):